Unknown

Dataset Information

0

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.

ABSTRACT: Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B-cells, is approved to treat aquaporin 4 (AQP4) IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and engineered for enhanced affinity to Fc receptor III-A (FCGR3A) receptors on natural killer cells to maximize antibody-dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of the FCGR3A gene (F158) was shown to decrease IgG-binding affinity and reduce rituximab (anti-CD20) efficacy for NMOSD attack prevention. In contrast, our current findings from inebilizumab-treated NMOSD patients indicate similar clinical outcomes between those with F158 and V158 allele genotypes.

SUBMITTER: Kim HJ 

PROVIDER: S-EPMC10723240 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B-cells, is approved to treat aquaporin 4 (AQP4) IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and engineered for enhanced affinity to Fc receptor III-A (FCGR3A) receptors on natural killer cells to maximize antibody-dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of the FCGR3A gene (F158) was shown to decrease IgG-bindi  ...[more]

Similar Datasets

Unknown Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
| S-EPMC9550749 | biostudies-literature
Unknown Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
| S-EPMC8054974 | biostudies-literature
Unknown High risk of postpartum relapses in neuromyelitis optica spectrum disorder.
| S-EPMC5705247 | biostudies-literature
Unknown Sleep abnormality in neuromyelitis optica spectrum disorder.
| S-EPMC4405292 | biostudies-literature
Unknown Neuromyelitis Optica Spectrum Disorder Presenting with Pseudoathetosis.
| S-EPMC5765249 | biostudies-literature
Unknown Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
| S-EPMC9545531 | biostudies-literature
Transcriptomics ATP mediates neuropathic pain of neuromyelitis optica spectrum disorder via microglial activation
2021-08-24 | GSE150598 | GEO
Unknown Association Between BDNF Val66Met Polymorphism and Optic Neuritis Damage in Neuromyelitis Optica Spectrum Disorder.
| S-EPMC6877654 | biostudies-literature
Unknown Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
| S-EPMC7183484 | biostudies-literature
Unknown Cognitive functions in Egyptian neuromyelitis optica spectrum disorder.
| S-EPMC7002275 | biostudies-literature